中低收入国家慢阻肺的诊断与治疗机会缺口
该研究在尼泊尔、秘鲁和乌干达三个中低收入国家站点,对1000名经人群筛查发现的慢阻肺患者,比较国际GOLD策略推荐干预与实际接受的干预。
要点
- 非药物干预缺口最大的是教育/疫苗接种、肺康复、戒烟和生物质烟雾暴露建议。
- 即使有维持治疗,30天费用超过低技能工人日均工资,难以负担。
核心结论
- 中低收入国家慢阻肺负担最重,但诊断和治疗机会大量缺失,改善诊断和可负担干预可立即获益。
研究设计与样本
- 在尼泊尔、秘鲁和乌干达三个中低收入国家站点,对1000名经人群筛查发现的慢阻肺患者进行比较研究。
- 比较国际GOLD慢阻肺策略文件推荐的干预与实际接受的干预,并计算药物可及性和可负担性成本。
主要发现
- 非药物干预最大未满足需求为教育和疫苗接种(适用于所有人)、肺康复(49%)、戒烟(30%)和生物质烟雾暴露建议(26%)。
- 既往诊断慢阻肺的47人中仅3人(6%)获得符合推荐的药物,更严重慢阻肺患者均未获得适当维持吸入剂。
- 即使维持治疗可及,30天治疗费用超过低技能工人日均工资,无法负担。
临床怎么用
- 在中低收入国家应加强慢阻肺筛查以提高诊断率,并优先提供可负担的教育、疫苗接种、肺康复和戒烟干预。
- 需关注维持吸入剂的可及性和可负担性,以改善慢阻肺患者治疗覆盖。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Chronic obstructive pulmonary disease (COPD) is a prevalent and burdensome condition in low- and middle-income countries (LMICs). Challenges to better care include more effective diagnosis and access to affordable interventions. There are no previous reports describing therapeutic needs of populations with COPD in LMICs who were identified through screening. Objectives: To describe unmet therapeutic need in screening-detected COPD in LMIC settings. Methods: We compared interventions recommended by the international Global Initiative for Chronic Obstructive Lung Disease COPD strategy document, with that received in 1,000 people with COPD identified by population screening at three LMIC sites in Nepal, Peru, and Uganda. We calculated costs using data on the availability and affordability of medicines. Measurement and Main Results: The greatest unmet need for nonpharmacological interventions was for education and vaccinations (applicable to all), pulmonary rehabilitation (49%), smoking cessation (30%), and advice on biomass smoke exposure (26%). Ninety-five percent of the cases were previously undiagnosed, and few were receiving therapy (4.5% had short-acting β-agonists). Only three of 47 people (6%) with a previous COPD diagnosis had access to drugs consistent with recommendations. None of those with more severe COPD were accessing appropriate maintenance inhalers. Even when available, maintenance treatments were unaffordable, with 30 days of treatment costing more than a low-skilled worker's daily average wage. Conclusions: We found a significant missed opportunity to reduce the burden of COPD in LMIC settings, with most cases undiagnosed. Although there is unmet need in developing novel therapies, in LMICs where the burden is greatest, better diagnosis combined with access to affordable interventions could translate to immediate benefit.
引用
- Florman KEH, Siddharthan T, Pollard SL, et al. Unmet Diagnostic and Therapeutic Opportunities for Chronic Obstructive Pulmonary Disease in Low- and Middle-Income Countries. Am J Respir Crit Care Med. 2023. PMID: 37369142. doi:10.1164/rccm.202302-0289OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。